We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bipartisan group of House members is continuing to push for passage of a bill allowing the government to negotiate drug prices for Medicare Part D, even while the government agency in charge of the program said the bill will not save money.
Sen. Chuck Grassley (R-Iowa), one of the most vocal opponents of government negotiation of Medicare costs, is considering using a filibuster to stop bipartisan direct negotiation legislation because he believes that its proponents may now have the votes to pass it.
A Centers for Medicare & Medicaid Services (CMS) committee is recommending that the agency soften a controversial proposal to require clinical trials it covers to enroll representatives of the populations Medicare serves as participants.
Congressional Democrats’ plan to reduce Medicare costs through government-run drug-price negotiation falls short of expectations and is an empty gesture that fails to give the government the leverage it needs, sources say.
The Senate is taking its first steps toward considering new Medicare drug price negotiating authority for the federal government with a hearing scheduled for Jan. 11.
Congressional Democrats’ plan to reduce Medicare costs through government-run drug-price negotiation falls short of expectations and is an empty gesture that fails to give the government the leverage it needs, sources say.
Congressional Democrats’ plan to reduce Medicare costs through government-run drug-price negotiation falls short of expectations and is an empty gesture that fails to give the government the leverage it needs, sources say. But the bill’s proponents reject that view.
Presumptive House Speaker Nancy Pelosi’s (D-Calif.) plan to prevent Republicans from offering alternatives to her Medicare direct negotiation legislation is not discouraging industry critics, who are still working to defeat the proposal.
PhRMA is tentatively supporting the Centers for Medicare & Medicaid Services’ (CMS) proposal to collect and share prescription drug plan data, but is concerned that the agency may overreach by using the information to compare different products.
Generics could see wider use in Medicare Part D next year, as many of the new drug plans participating in the program substitute generics for their brand equivalents, according to a new side-by-side examination of the 2006 and 2007 programs by the Kaiser Family Foundation.